Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4

Xenobiotica

Volumn 28, Issue 1, 1998, Pages 1-13

  Chesne C ^a   Guyomard, C ^a   Guillouzo, A ^b   Schmid, J ^c   Ludwig, E ^c   Sauter, T ^c  

^a BIOPREDIC   (France)

^b INSERM   (France)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME; CYTOCHROME P450; KETOCONAZOLE; MELOXICAM; NIFEDIPINE; OXIDOREDUCTASE; OXYGENASE; TOLBUTAMIDE;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROXYLATION; KINETICS; LIVER; LIVER CELL; LIVER METABOLISM; METABOLITE; MICROSOME; OXIDATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; KINETICS; LIVER; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SUBSTRATE SPECIFICITY; THIAZINES; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 0031985363     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982598239704     Document Type: Article

References (29)

1. BRADFORD, M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248-254.
2. BREIMER, D. D., 1995, An integrated molecular and kinetic/dynamic approach to metabolism in drug development. In European Cooperation in the Field of Scientific and Technical Research. COST B1 Conference on Variability and Specificity in Drug Metabolism (Brussels: European Commission), pp. 2-19.
3. DISLERATH, L. M., REILLY, P. E., MARTIN, M. V., DAVIS, G. G., WILKINSON, G. R. and GUENGERICH, F. P., 1985, Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 260, 9057-9067.
4. ENGELHARDT, G., BÖGEL, R., SCHNITZLER, C. and UTZMANN, R., 1995a, Meloxican: influence on arachidonic acid metabolism. Part II: In vivo findings. Biochemical Pharmacology, 51, 21-38.
5. ENGELHARDT, G., HOMMA, D., SCHLEGEL, K., UTZMANN, R. and SCHNITZLER, C., 1995b, Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflammation Research, 44, 423-433.
6. GOLSTEIN, J. A. and DE MORAIS, S. M. F., 1994, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4, 285-299.
7. GUENGERICH, F. P., MARTIN, M. V., BEAUNE, P. H., KREMERS, P., WOLF, T. and WAXMAN, D. J., 1986, Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 261, 5051-5060.
8. GUGUEN-GUILLOUZO, C. and GUILLOUZO, A., 1986, Methods for preparation of adult and fetal hepatocytes. In Isolated and Cultured Hepatocytes, edited by A. Guillouzo and C. Guguen-Guillouzo (Paris and London: INSERM and John Libbey Eurotext), pp. 1-12.
9. GUILLOUZO, A. and CHESNE, C., 1996, Xenobiotic metabolism in epithelial cell cultures.. In Epithelial Cell Culture: A Practical Approach, edited by A. J. Shaw (Oxford: IRL), pp. 67-85.
10. HOSIE, J., DISTEL, M. and BLUHMKI, E., 1996, Meloxicam in osteoarthritis: a 6-month double blind comparison with diclofenac sodium. British Journal of Rheumatology, 35 (suppl 1), 39-13.
11. ICHIHARA, S., TOMISAWA, H., FUKAZAWA, H. and TATEISHI, M., 1985, Involvement of leucocyte peroxidases in the metabolism of tenoxicam. Biochemical Pharmacology, 34, 1337-1338.
12. KLOTZ, A. V., STEGEMAN, J. J. and WALSH, C., 1984, An alternative 7-ethoxyresorufin O-deethylase activity assay: a continuous visible spectrophotometric method for measurement of cytochrome P-450 monooxygenase activity. Analytical Biochemistry, 140, 138-145.
13. KOOP, D. R., 1986, Hydroxylation of p-nitrophenol by rabbit ethanol inducible cytochrome P-450 isozyme IIIa. Molecular Pharmacology, 29, 399-404.
14. KRONBACH, T., MATHYS, D., GUT, J., CATIN, T. and MEYER, U. A., 1987, High-performance liquid chromatographic assays for bufuralol 1-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Analytical Biochemistry, 162, 24-32.
15. MINERS, J. O., REES, D. L. P., VALENTE, L., VERONESE, M. E. and BIRKETT, D. J., 1995, Human hepatocyte cytochrome P-450 2C9 catalyzes the rate limiting pathway of torsemide metabolism. Journal of Pharmacology and Experimental Therapeutics, 272, 1076-1081.
16. MITCHELL, J. A., AKARASEREENONT, P., THIERMERMANN, C., FLOWER, R. J. and VANE, J. R., 1994, Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proceedings of the National Academy of Sciences, USA, 90, 11693-11697.
17. ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONAZALEZ, F. J. and TSUTSUI, T., 1996, Specificity of substrate and inhibitor probes for cytochromes P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681-693.
18. REGINSTER, J. Y., DISTEL, M. and BLUHMKI, E., 1996, A double blind three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. British Journal of Rheumatology, 35 (Suppl 1), 17-21.
19. RETTIE, A. E., KORZEKWA, K. R., KUNZE, K. L., LAWRENCE, R. F., EDDY, A. C., AOYAMA, T., GELBOIN, H. V., GONZALEZ, F. J. and TRAGER, W. F., 1992, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-450C29 in the etiology of (S)-warfarin drug interactions. Chemical Research of Toxicology, 5, 54-59.
20. ROMKES, M., FALETTO, M. B., BLAISDELL, J. A., RAUCY, J. L. and GOLDSTEIN, J. A., 1991, Cloning and expression of complementary DNAs for multiple members of the human cytochrome P-450IIC. Biochemistry, 30, 3247-3255.
21. SCHMID, J., BUSCH., U., TRUMMLITZ, G., PROX, A., KASCHKE, S. and WACHSMUTH, H., 1995a, Meloxicam: metabolic profile and biotransformation products in the rat. Xenobiotica, 25, 1219-1236.
22. SCHMID, J., BUSCH, U., HEINZEL, G., BOZLER, G., KASCHKE, S. and KUMMER, M., 1995b, Meloxicam: pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metabolism and Disposition, 23, 1206-1213.
23. SCHMID, J. and ROTH, W., 1987, HPLC-procedure for drug metabolism studies: the potential of column switching. In Drug Metabolism, From Molecules to Man, edited by D. J. Benford, J. W. Bridges and C. G. Gibson (London: Taylor & Francis), pp. 213-216.
24. SEIBERT, K., ZHANG, Y., LEAHY, K., HAUSER, S., MASFERRER, J., PERKINS, W., LEE, L. and ISAKSON, P., 1994. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proceedings of the National Academy of Sciences, USA, 91, 12013-12017.
25. SHIMADA, T., MISONO, S. K. and GUENGERICH, F. P., 1986. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 261, 909-921.
26. STUBBINS, M. J., HARRIES, L. W., SMITH, G., TARBIT, M. H. and WOLF, C. R., 1996, Genetic analysis of the human cytochrome P-450 CYP2C9 locus. Pharmacogenetics, 6, 432-439.
27. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6, 341-349.
28. TÜRCK, D., SU, C. A. P. F., HEINZEL, G., BUSCH, U., BLUHMKI, E. and HOFFMANN, J., 1997, Lack of interaction between meloxicam and warfarin in healthy volunteers. European Journal of Clinical Pharmacology, 51, 421-425.
29. ZHAO, J., LEEMANN, T. and DAYER, P., 1992, In vitro oxidation of oxicam NSAIDs by a human liver cytochrome P-450. Life Sciences, 51, 575-581.